<?xml version="1.0" encoding="UTF-8"?>
<p>β-Pulegone (
 <italic>p</italic>-menth-4(8)-en-3-one) is a monocyclic monoterpenoid ketone found in European pennyroyal (
 <italic>Mentha pulegium</italic> L.) (67.6–86.7%) [
 <xref rid="B23-ijms-22-02380" ref-type="bibr">23</xref>], North American pennyroyal (
 <italic>Hedeoma pulegioides</italic> (L.) Pers.) (61.3–82.3%) [
 <xref rid="B23-ijms-22-02380" ref-type="bibr">23</xref>], lesser calamint (
 <italic>Calamintha nepeta</italic> (L.) Savi) (17.6–76.1%) [
 <xref rid="B47-ijms-22-02380" ref-type="bibr">47</xref>], buchu (
 <italic>Agathosma betulina</italic> (P.J. Bergius) Pillans) (pulegone chemotype) (31.6–73.2%) [
 <xref rid="B29-ijms-22-02380" ref-type="bibr">29</xref>,
 <xref rid="B30-ijms-22-02380" ref-type="bibr">30</xref>], Turkish pennyroyal (
 <italic>Micromeria fruticosa</italic> (L.) Druce) (66.7%) [
 <xref rid="B23-ijms-22-02380" ref-type="bibr">23</xref>], and buchu (
 <italic>Agathosma crenulata</italic> L.) (diosphenol chemotype) (0.6–4.5%) [
 <xref rid="B29-ijms-22-02380" ref-type="bibr">29</xref>]. Following oral consumption, pulegone is metabolized into at least 14 metabolites including menthofuran and 8-pulegone aldehyde which are more toxic than pulegone itself [
 <xref rid="B173-ijms-22-02380" ref-type="bibr">173</xref>,
 <xref rid="B174-ijms-22-02380" ref-type="bibr">174</xref>,
 <xref rid="B175-ijms-22-02380" ref-type="bibr">175</xref>]. Pulegone metabolites are the ones responsible for the toxicity since menthofuran is hepatotoxic and 
 <italic>p</italic>-cresol is a toxin and glutathione-depleting agent [
 <xref rid="B176-ijms-22-02380" ref-type="bibr">176</xref>,
 <xref rid="B177-ijms-22-02380" ref-type="bibr">177</xref>]. γ-Ketoenal, a reactive metabolite of pulegone, causes hepatic injury via covalently binding to cellular proteins in the liver [
 <xref rid="B176-ijms-22-02380" ref-type="bibr">176</xref>,
 <xref rid="B177-ijms-22-02380" ref-type="bibr">177</xref>]. Treatment with cytochrome P-450 inhibitors (SKF-525A, metyrapone, piperonyl butoxide, and carbon disulfide) blocked pulegone hepatotoxicity, indicating the involvement of cytochrome P-450 in pulegone metabolism [
 <xref rid="B175-ijms-22-02380" ref-type="bibr">175</xref>,
 <xref rid="B178-ijms-22-02380" ref-type="bibr">178</xref>]. Unlike menthofuran, (1
 <italic>R</italic>)-(+)-β-pulegone was reported to deplete hepatic glutathione in in vitro experiments, and upon i.p. injection into rats (at 150 mg/kg) or mice (at 300 mg/kg) [
 <xref rid="B173-ijms-22-02380" ref-type="bibr">173</xref>,
 <xref rid="B179-ijms-22-02380" ref-type="bibr">179</xref>]. In rats, (1
 <italic>R</italic>)-(+)-β-pulegone (i.p., at 300 mg/kg) caused severe damage to the endoplasmic reticulum that led to cell death [
 <xref rid="B180-ijms-22-02380" ref-type="bibr">180</xref>]. (1
 <italic>R</italic>)-(+)-β-Pulegone treatment was found to destroy hepatic cytochrome P-450 enzymes [
 <xref rid="B178-ijms-22-02380" ref-type="bibr">178</xref>,
 <xref rid="B180-ijms-22-02380" ref-type="bibr">180</xref>,
 <xref rid="B181-ijms-22-02380" ref-type="bibr">181</xref>,
 <xref rid="B182-ijms-22-02380" ref-type="bibr">182</xref>].
</p>
